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AbstrACt
Introduction There are few robust and directly 
comparable studies of the epidemiology of psychotic 
disorders in the Global South. INTREPID II is designed to 
investigate variations in untreated psychotic disorders 
in the Global South in (1) incidence and presentation (2) 
2- year course and outcome, (3) help- seeking and impact, 
and (4) physical health.
Methods INTREPID II is a programme of research 
incorporating incidence, case–control and cohort studies 
of psychoses in contiguous urban and rural areas in India, 
Nigeria and Trinidad. In each country, the target samples 
are 240 untreated cases with a psychotic disorder, 240 
age- matched, sex- matched and neighbourhood- matched 
controls, and 240 relatives or caregivers. Participants 
will be followed, in the first instance, for 2 years. In 
each setting, we have developed and are employing 
comprehensive case- finding methods to ensure cohorts 
are representative of the target populations. Using 
methods developed during pilot work, extensive data are 
being collected at baseline and 2- year follow- up across 
several domains: clinical, social, help- seeking and impact, 
and biological.
Ethics and dissemination Informed consent is sought, 
and participants are free to withdraw from the study at any 
time. Participants are referred to mental health services 
if not already in contact with these and emergency 
treatment arranged where necessary. All data collected are 
confidential, except when a participant presents a serious 
risk to either themselves or others. This programme has 
been approved by ethical review boards at all participating 
centres. Findings will be disseminated through 
international conferences, publications in international 
journals, and through local events for key stakeholders.
IntroduCtIon
Psychotic disorders, such as schizophrenia, 
affect more than 23 million people worldwide, 
contribute substantially to the global burden 
of disease and are associated with high rates 
of disability and mortality.1–3 However, there 
are striking global inequities in our knowl-
edge of psychoses. Over 85% of the world’s 
population lives in Asia, Africa, Latin America 
and the Caribbean (referred to here as the 
Global South; the term Global South refers to 
countries in Asia, Africa, Latin America and 
the Caribbean and does not necessarily refer 
to the geographical south, see eg, http://
www. fc- ssc. org/ en/ partnership_ program/ 
south_ south_ countries), but only a small 
fraction of research on psychotic disorders is 
done in these settings.4 5 This has two implica-
tions. First, our knowledge of psychotic disor-
ders, especially of the basic epidemiology, 
of associated risk factors, and of course and 
outcome, is incomplete and may be distorted. 
We do not know whether psychoses manifest, 
occur and develop in the same ways around 
the world. Second, we do not have robust 
and replicated findings on which to base 
the development of accessible, humane and 
effective services and public health initia-
tives in low resource settings. Conducting 
studies in a range of countries and contexts 
is essential to improve our understanding of 
the nature of psychotic disorders globally and 
to provide a much- needed evidence base to 
inform the development and implementa-
tion of effective interventions and services in 
diverse settings.
strengths and limitations of this study
 ► Comprehensive case- finding methods, building on 
extensive pilot work, to generate as complete a 
sample as possible and reduce selection bias.
 ► Inclusion of population- based, matched controls.
 ► Direct comparability of methods across settings.
 ► Potential trade- offs between cross- setting compa-
rability and local validity.
 ► Use of retrospective self- reports for several fac-
tors, which are potentially subject to recall bias and 
which create challenges in establishing the direction 
of associations.
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We established the International Programme of 
Research on Psychotic Disorders (INTREPID) II—the 
first multicountry study in four decades in the Global 
South—to extend our knowledge of psychotic disorders 
in diverse settings. This builds on extensive feasibility and 
pilot work5–7 (INTREPID I; see Supplementary Materials, 
online supplementary appendix 1).
AIM, objECtIvEs And rAtIonAlE
Our aim is to investigate variability in incidence, presen-
tation, outcome and impact of untreated psychotic 
disorders in three diverse countries of the Global South—
India, Nigeria and Trinidad—through four intercon-
nected studies.
study 1: incidence, presentation and risk
Objective: To investigate the incidence and presentation 
of untreated psychotic disorders in each setting and asso-
ciated risk factors.
Psychotic disorders are highly heterogenous in inci-
dence, presentation and course and outcome. For 
example, the incidence of schizophrenia and other 
psychoses varies markedly across populations and social 
groups.8 9 Rates are higher among men,9 in urban areas,10 
and in many—but not all—migrant and minority ethnic 
populations.11 However, little is known about the inci-
dence of psychoses in the Global South, beyond a small 
number of studies,5 12 and we cannot assume that findings 
from the Global North generalise to other settings. There 
is tentative evidence, for example, that findings from the 
Global North, such as the association with urbanicity, may 
not apply universally.13–15 Further, the phenomenology 
(ie, symptom profile) of psychotic disorders is highly 
varied. Individuals experience a range of symptoms, in 
various combinations, spanning multiple dimensions, 
including symptoms of reality distortion (ie, delusions, 
hallucinations), thought disturbance, mania, depres-
sion and poverty of affect, speech and volition. There is 
some evidence that symptom profiles vary across social 
and cultural contexts. For example, the Determinants of 
Outcome of Severe Mental Disorders (DOSMeD) study, 
a 2- year cohort study conducted in 10 countries by the 
WHO, found that non- affective acute remitting psychoses 
(ie, presentations characterised by rapid onset, symptoms 
of reality distortion and quick remission) were around 
10 times more common in settings in the Global South 
compared with the Global North,16 but these findings 
have not been replicated.
There is robust evidence from the Global North impli-
cating an array of factors that likely combine in complex 
ways to increase risk. These include genetic,17 18 neuro-
developmental markers (eg, birth complications, poor 
premorbid function),19 20 exposure to trauma and other 
social disadvantages,21 22 migration and minority ethnic 
status11 23 and substance use.24 25 Further, there is growing 
evidence that specific risk factors are associated with 
particular symptoms.18 26–28 For example, there is evidence 
of an association between social risk factors and specific 
symptoms of reality distortion,29–36 that is, more delusions 
and hallucinations. It may be, then, that variations in inci-
dence and presentation between settings reflect different 
population distributions in relevant risks. However, little 
research has explored these associations in the Global 
South.
Studying variations in incidence and presentation 
and associated risks in diverse populations may provide 
important insights into the aetiology of psychoses and 
provide a basis for developing public health strategies to 
reduce the burden of psychotic disorders. In this study, 
we will test several primary hypotheses on whether varia-
tions and associations observed in the Global North hold 
in more diverse settings.
study 2: course and outcome
Objective: To investigate 2- year course and outcome of 
psychotic disorders and associated factors.
The long- term course and outcome of psychoses 
following a first episode is highly variable. Evidence from 
the Global North suggests that, over a period of 5–10 
years, around half of those with a psychotic disorder 
recover symptomatically (ie, are symptom free for a 
period of 2 or more years),37–40 but the proportion who 
achieve both symptom and social recovery is much lower 
(8%–20%),41 with high levels of enduring unemploy-
ment and social isolation.42–47 Several factors are associ-
ated with poor symptom and social outcomes, including 
premorbid difficulties, baseline symptom type (ie, nega-
tive symptoms) and severity, cognition, long duration of 
untreated psychosis and persistent substance use.48–50 As 
with incidence and presentation, it seems that course and 
outcome vary by context. The DOSMeD study51 and the 
International Study of Schizophrenia (ISoS)12 reported 
better symptom and social outcomes for psychotic disor-
ders in developing (ie, Global South) versus developed 
(ie, Global North) countries, which has often been 
attributed to greater family support and community cohe-
sion in more traditional societies. There are, however, 
several well- documented methodological limitations 
to the DOSMeD and ISoS, not least that the number of 
countries included from the Global South is small (n=3). 
Subsequent research appears to show greater variation 
between and within countries in the Global South.52
In this study, we will describe and compare course and 
outcome at 2 years within and between settings, and then 
test several primary hypotheses on the nature and origins 
of any observed variations.
study 3: help-seeking and impact
Objective: To investigate: (1) help- seeking and (2) the 
impact of psychotic disorders on individuals and fami-
lies, using a combination of quantitative and qualitative 
approaches.
Many people with psychotic disorders in the Global 
South receive no formal (biomedical) treatment or 
begin treatment well after the critical window when early 
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intervention is most effective.6 53 Formal care in many 
countries often falls below minimum quality standards,54 
and much of the burden of care falls on families. The 
use of traditional and religious healing for mental health 
problems is widespread in both Africa and Asia, even 
among those who also consult mental health services.55 56 
Such services also exist in the Caribbean, but are more 
disparate, less specialised and typically used in addition—
rather than as an alternative— to formal health services.5 6 
Practitioners of traditional medicine and faith healing fill 
a major gap in countries where formal care is scarce,57 
but the nature and quality of the care they provide is 
highly variable.58 Human rights abuses have been widely 
documented in both traditional healing sites and formal 
mental health services around the world.59 In part because 
of this, family members provide a large proportion of 
care for people with long- standing problems—including 
severe mental disorders—in the Global South.60 Caring 
for a relative with a psychotic disorder can have a major 
physical, emotional and economic impact on families, 
particularly in households with limited resources.61–63 
There is also evidence of high levels of stigma in many 
countries of the world, including India,64 Nigeria65 and 
Trinidad.66
To plan appropriate services and understand differ-
ences in outcomes, further in- depth evidence, both 
quantitative and qualitative, is needed about how indi-
viduals and families respond to psychotic disorders and 
their needs and experiences, including the treatment 
they receive, within local contexts. In this study, we will 
first describe and compare, between and within settings 
(eg, by gender, by age and so on), the types and extent of 
contacts with formal services and other providers and the 
impact (ie, on quality of life) and burden of psychoses for 
individuals and families. We will then test, using quantita-
tive data, several related primary hypotheses and address, 
using in- depth qualitative data, questions concerning 
how individuals and families make sense of and respond 
to psychoses and the impacts on individuals and families.
study 4: physical health
Objective: To investigate the types and prevalence of 
physical health problems and related biological markers.
In the Global North, those with a psychotic disorder 
have higher rates of physical health problems and higher 
rates of all- cause mortality,67 particularly cardiovascular 
disease and metabolic syndrome,68 which may result 
from both antipsychotic medication use and lifestyle 
factors.69–71 Comorbidity of physical and mental health 
problems is likely to impact negatively on quality of life 
and recovery.72 Our knowledge of the physical health of 
people with psychoses in the Global South is much more 
limited,73 but suggests that there is also a mortality gap 
compared with the general population and this may 
be related to similar health problems as in the Global 
North.74 75 For example, evidence from India suggests that 
metabolic syndrome is common76 and there are rising 
rates of diabetes and cardiovascular disease in India,77 
Nigeria78 and Trinidad.79 It may also be, however, that 
the types of physical health problems (eg, malnutrition; 
infectious diseases; injury due to accident, violence) in 
developing countries differ from those common in devel-
oped countries.
In this study, we will describe and compare, between 
and within settings, markers and measures of physical 
health problems between cases and age- matched and sex- 
matched controls, and test hypotheses concerning the 
nature and origins of variations in physical health within 
and between settings.
FEAsIbIlIty And pIlot work
See online supplementary appendix 1 in our Supplemen-
tary Materials for a description of our feasibility and pilot 
work.
sEttIngs
INTREPID II is a collaboration between the Schizo-
phrenia Research Foundation (SCARF; Chennai), the 
University of Ibadan (Nigeria), the University of the West 
Indies at St Augustine (Trinidad), the London School of 
Hygiene and Tropical Medicine (UK) and the Institute 
of Psychiatry, Psychology & Neuroscience, King's College 
London (UK).
The study settings, in India, Nigeria and Trinidad, were 
selected to maximise potential comparisons between sites 
and with existing datasets. They represent three econom-
ically, socially and culturally diverse areas, on three 
continents, each undergoing rapid economic and social 
transformations.
In each setting, our catchment areas comprise urban 
and rural areas with total populations of around 500 000 
adults aged 18–64 years. In Nigeria, the catchment area 
comprises three contiguous Local Government Areas 
in and around the city of Ibadan in Oyo State: Ibadan 
North East, Ibadan South East and Ona- Ara (total adult 
population ~584 000, population density 914–18 356 per 
km2). In Trinidad, the catchment area comprises the 
municipalities of Arima, Tunapuna–Piarco, Chaguanas, 
Port of Spain, San Juan/Laventille, Diego Martin and 
Sangre Grande (total adult population ~487 000, popu-
lation density 82–3090 per km2). In India the catchment 
area consists of three contiguous taluks, Chengalpattu, 
Uthiramerur and Maduranthakam, located south of 
Chennai, in the district of Kancheepuram in the state of 
Tamil Nadu (total adult population ~600 000, population 
density 361–737 per km2).
MEthods
overview
INTREPID II comprises four interconnected studies 
(figure 1; see Strobe Statement, online supplementary 
materials). As a basis for these studies, we are identi-
fying, assessing and following, in each catchment area, 
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Figure 2 Summary of methodology.
Figure 1 Structure of INTREPID II.
population- based cohorts of cases (individuals with an 
untreated psychotic disorder) and controls (individuals 
with no history of a psychotic disorder) (figure 2).
In each setting, using methods and infrastructure devel-
oped during our feasibility and pilot work, INTREPID I, 
we will identify, assess and follow at 2 years cohorts of 
240 untreated (incident) cases with a psychotic disorder 
(total=720) and 240 matched controls (total=720). Our 
inclusion and exclusion criteria for cases are in line with 
those used in previous studies, including the WHO multi-
country studies,12 and are purposefully broad to capture 
heterogeneity and to allow subanalyses by duration of 
untreated psychosis (table 1).
sample 1: cases
To estimate incidence, we aim to identify all individuals 
with an untreated psychotic disorder (cases) within each 
catchment area. Untreated is defined as never having 
received treatment with anti- psychotic medication for 
one continuous month prior to the start of the case- 
finding period.
In each catchment area, we are using a multipronged 
approach to case identification. First, using procedures 
developed in INTREPID I, we have established compre-
hensive case detection systems by mapping and seeking 
to engage a comprehensive set of service providers and 
community key informants who may encounter individ-
uals with psychotic disorders within the catchment area. 
This includes the professional sector (specialist and 
generalist services; public, private and third sector), the 
folk sector (including traditional and religious services) 
and the popular sector (ie, informal sources of support). 
Second, we give providers and informants materials 
developed in our pilot work that detail, using local 
terms and language, the experiences and behaviours 
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Cases
 ► Age 18–64 years  ► Transient psychotic 
symptoms resulting from 
acute intoxication as 
defined by ICD-10
 ► Currently resident in 
catchment area (primary 
residence)
 ► Moderate or severe 
learning disability, as 
defined by ICD-10




 ► Clinically manifest organic 
cerebral disorder (eg, 
infections, parasitic, toxic, 
cerebrovascular, epilepsy 
and brain injury), as 
defined by ICD-10
 ► Not treated with 
antipsychotic medication 
for more than one 
continuous month prior 
to the start of initial case 
identification
Controls
 ► Age 18–64 years  ► Past or current ICD-10 
psychotic disorder
 ► Currently resident in 
catchment area (primary 
residence)
 ► Moderate or severe 
learning disability, as 
defined by ICD-10
 ► Same gender as index 
case
 ► Clinically manifest organic 
cerebral disorder (eg, 
infections, parasitic, toxic, 
cerebrovascular, epilepsy 
and brain injury), as 
defined by ICD-10
 ► Within 5 years of age of 
index case
Relatives
 ► Age 18 and above  ► Insufficient contact 
with case to provide 
information on family 
burden or mental health
 ► Relative or carer of a case 
who has consented to 
participate in the current 
study
that characterise psychosis. Third, in each catchment 
area, researchers check with each provider and infor-
mant regularly and conduct regular checks of admis-
sions ledgers and registers for in- patient and out- patient 
services (where these exist), to identify potential cases. In 
addition, in rural villages in Chennai and Ibadan, field 
workers visit village meeting points to enquire about 
potential cases. Potential cases are then screened for 
inclusion using the Screening Schedule for Psychosis,51 an 
instrument that has been widely used in epidemiological 
studies of psychoses. Those who screen positive and who 
meet inclusion criteria are approached and informed 
consent sought.
Case- finding began on 1 May 2018 and will conclude 
on 30 April 2020. At the end of the case- finding period, 
we will conduct leakage studies in each setting to identify 
possible cases meeting our inclusion criteria who may not 
have been identified. Each research team will systemati-
cally re- check admissions ledgers and registers for in- pa-
tient and out- patient services and complete final checks 
with healers and key informants.
All eligible cases identified through the incidence 
study are invited to participate in the programme. 
Rates of refusal are documented and basic data (ie, age, 
gender, area of residence, sector of identification, and 
where possible ethnicity, religion, duration of untreated 
psychosis and mode of onset) are collected for those who 
decline to participate, or who it is not possible to inter-
view, to assess non- response bias.
sample 2: controls
Age- matched, sex- matched and neighbourhood- matched 
controls are recruited to provide indicative population 
data against which to compare cases in terms of hypoth-
esised risk factors, social outcomes and physical health. 
We use the Psychosis Screening Questionnaire to collect 
information on any current or past experiences of 
psychosis.80 In the absence of a readily accessible sampling 
frame to randomly select potential controls, we map the 
10 nearest neighbouring households for each case, listing 
all residents in these dwellings by sex and age. All poten-
tial controls for the case (defined as the same gender and 
±5 years of age) are then approached in random order, 
until an eligible control is identified. When no match 
is identified the process is repeated. This approach was 
successfully piloted in all settings.
sample 3: relatives and caregivers
We seek consent from each case to approach a close 
relative or caregiver to participate in the study. We 
then approach each designated relative to seek his/her 
consent. The primary purposes of including relatives are 
to corroborate and extend information from cases (eg, 
physical health and illness), to collect information on 
premorbid adjustment, family history of mental disorder 
and other risk factors, and to collect information on 
family responses to psychosis, help- seeking and impact 
(burden) on family.
Follow-up
All participants will be followed for 2 years. To facilitate 
this, we collect detailed contact information at baseline 
(address, telephone number, email address if applicable 
and service provider details) from each case and control, 
including details of a relative or friend who can be 
contacted to trace the individual. In addition, to maintain 
contact and minimise attrition, we contact participants 
every 6 months, by telephone or in person, to confirm 
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or update contact details. Based on our pilot work, we 
expect to re- assess around 80% of cases and controls 2 
years after initial identification.
sample size
In each setting, we anticipate (based on pilot findings) 
identifying around 300 untreated incident cases. Of those, 
given an expected refusal rate of 20% of all eligible cases 
(based on our pilot work), we anticipate recruiting ~240 
cases (total=720), and 240 individually matched controls 
(total=720). These sample sizes are larger than most 
previous studies5 52 and provide good statistical power to 
test our hypotheses (ie, >80% at p=0.05). For example: 
(1) with samples of around 300 untreated incident cases 
in each setting, we will have over 80% power to detect an 
incidence rate ratio of 1.5 (or greater) between two areas 
(eg, urban vs rural), if the incidence rate in the lowest, 
risk area is 20 per 100,000; (2) with a sample of 240 cases 
and 240 controls in each setting, we will have over 80% 
power to detect an OR of 2.0 (or greater) in case–control 
comparisons when the prevalence of exposure (risk 
factor) is at least 15% in controls; (3) using gender as an 
example, with a sample of 192 cases followed at 2 years 
in each setting, we will have 80% power (or greater) to 
detect a difference in the proportion of cases with a poor 
outcome (eg, continuously psychotic) of 0.20 (20%) or 
greater, when the proportion of men with a poor outcome 
is 0.40 and the proportion of women is 0.20 (ie, equiva-
lent to an OR of ~2.5).
data collection
To test the hypotheses and address the research questions 
of our four studies, we collect information from cases, 
relatives and controls at baseline and at a 2- year follow- up. 
A summary of the measures and the study to which they 
relate is provided in table 2. All, where necessary, have 
been translated into local languages and back translated 
to check equivalence.
All those who consent are interviewed and assessed by 
trained research workers using structured instruments 
and protocols either at home or at a local clinic. For 
participants who are in contact with health services, inter-
view data are supplemented with reference to clinical 
notes, with participants’ consent.
Interviews and assessments are conducted by 
researchers fluent in the local language. To ensure consis-
tency of methods across settings, all researchers are fully 
trained using a mixture of online materials and exercises, 
with feedback, and face to face training, delivered both 
by the UK team and locally by senior researchers under 
the supervision of the country principal investigators 
(PIs). All PIs are experienced psychiatrists with extensive 
backgrounds in both national and international research. 
Inter- rater reliability for core instruments that require 
rater judgement will be tested regularly across settings 
using video- recorded interviews with cases and controls 
to ensure that the measures are applied consistently 
throughout the duration of the programme. Responses 
will be triangulated with relative reports and, where appli-
cable, clinical records.
reliability
All measures will be applied identically, by the same 
research team, for both cases and controls (where 
measures apply to both groups). Researchers from 
across the field settings rated video- taped interviews at 
study onset and their ratings were compared with gold 
standard responses developed by the PIs. The mean and 
range for the proportion of scores that matched the gold 
standard ratings for each instrument, or were within an 
acceptable margin, were as follows: Schedules for Clin-
ical Assessment in Neuropsychiatry (SCAN), 87% (85%–
88%); Disability Assessment Schedule 88% (85%–92%), 
Personal and Psychiatric History Schedule 76% (73%–
84%), Global Assessment of Function 12.5% (0%–50%). 
Feedback was provided to the research workers and their 
ratings will continue to be monitored at repeated inter-
vals throughout the study.
Analysis plan
We will use standard summary statistics, with indicators of 
spread and precision as appropriate (eg, crude incidence 
rates per 100 000 person years, with 95% confidence 
intervals) to describe the data. We will then use appro-
priate regression models to compare data between and 
within settings (eg, Poisson regression for incidence rates 
and other count data; Cox regression for time- to- event 
data; logistic regression (including multinomial) for cate-
gorical data (eg, course type); and linear regression for 
continuous data (eg, General Assessment of Functioning 
score, blood pressure)). In building regression models, 
we will first fit univariable models, then test for effect 
modification by core variables (eg, gender, age, setting 
and time) and finally adjust for putative confounders 
of each hypothesised association by fitting multivariable 
models.
Where appropriate, we will use multiple imputations 
to deal with missing data. In addition, or where assump-
tions necessary for imputation are not met, we will (re)
conduct analyses on participants with complete data 
only. Where possible, analyses based on imputed data will 
be presented, with complete data analyses presented as 
sensitivity analyses in online supplementary materials.
Framework Analysis will be used to analyse qualita-
tive data,81 adopting an iterative process of reading and 
annotating transcripts to identify salient themes, which 
will form the basis for comparisons between and within 
settings.
EthICs And dIssEMInAtIon
Informed consent will be sought from all eligible partici-
pants, and participants will be free to withdraw from the 
study at any time. Capacity to consent will be assessed by 
trained researchers at the point of seeking consent. If 
at any point, there is concern for the mental or physical 
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health or welfare of participants, researchers will discuss 
immediately with the country PI, who will arrange for 
assessment and referral to the appropriate local mental 
or other health service, including emergency treatment 
where necessary.
All data collected will be kept confidential, except 
with the express consent of the patient to share informa-
tion with healthcare professionals, or in cases where the 
participant poses a serious risk either to themselves or to 
others.
This study has been approved by the ethical review 
boards of King’s College London (reference number: 
HR-17/18-5601), London, UK; London School of 
Hygiene and Tropical Medicine (reference number: 
15807), SCARF, Chennai, India; the University of Ibadan, 
Ibadan, Nigeria; the University of the West Indies, St 
Augustine, Trinidad; and the North West, North Central, 
and Eastern Regional Health Authorities of Trinidad.
We will disseminate our findings widely, including 
through international conferences and publications in 
international journals, and through locally organised 
events for service users, service providers and policy 
makers.
pAtIEnt And publIC InvolvEMEnt
Patients and members of the public were not involved in 
the design or conduct of the study. However, the research 
teams in each study setting are liaising with local service 
user and family organisations to discuss the interpreta-
tion of the findings, to consider potential recommenda-
tions arising from the evidence generated and to devise 
and implement local dissemination plans.
ongoIng And plAnnEd ExtEnsIons
In addition to enabling us to investigate and test our 
primary research questions and hypotheses, INTREPID 
II establishes in each setting platforms and infrastructure 
for the conduct of other studies. Building on this, several 
extensions to INTREPID II are ongoing or planned. Four 
of these are detailed in online supplementary appendix 
2 (see Supplementary Materials, online supplementary 
appendix 2).
Author affiliations
1Health Service & Population Research department, Institute of Psychiatry 
Psychology and Neuroscience, London, UK
2ESRC Centre for Society and Mental Health, King's College London, London, UK
3WHO Collaborating Centre for Research and Training in Mental Health, 
Neuroscience and Substance Abuse, Department of Psychiatry, University of Ibadan, 
Ibadan, Oyo, Nigeria
4Schizophrenia Research Foundation, Chennai, India
5Department of Psychiatry, The University of the West Indies at Saint Augustine 
Faculty of Medical Sciences, Saint Augustine, Tunapuna–Piarco, Trinidad and 
Tobago
6Department of Epidemiology, Harvard University T H Chan School of Public Health, 
Boston, Massachusetts, USA
7Epidemiology and Population Health, London School of Hygiene and Tropical 
Medicine, London, UK
8London School of Hygiene and Tropical Medicine, London, UK
9Department of Psychiatry, University of Ibadan College of Medicine, Ibadan, Oyo, 
Nigeria
10Department of Psychosis Studies, Institute of Psychiatry Psychology and 
Neuroscience, London, UK
twitter Tessa Roberts @INTREPID_psych
Acknowledgements The authors wish to thank the research teams at the 
University of Ibadan, the Schizophrenia Research Foundation and the University of 
the West Indies for their ongoing work on this programme.
Contributors TR contributes to the overall coordination of the programme and 
drafted and revised the manuscript, based on the funded grant proposal written by 
CM, OG, RT, GH, HAW, AC and RMM to the UK Medical Research Council. RT, OG and 
GH contributed to the design the programme, lead the programme in India, Nigeria 
and Trinidad, respectively, and contributed to review and revision of the manuscript. 
AC, HAW and RMM contributed to the design of the programme and to review 
and revision of the manuscript. GME contributes to the overall coordination of the 
programme and contributed to review and revision of the manuscript. SJ, BO, JLP 
and CD coordinate the programme in India (SL), Nigeria (BO) and Trinidad (JLP and 
CD) and contributed to review and revision of the manuscript. CM led the design 
of the programme and the study methods, leads the programme, contributed 
to drafting and revising the manuscript, and provided guidance and supervision 
throughout the preparation of the manuscript.
Funding This programme is funded by the UK Medical Research Council (MRC) 
(MRC Reference: MR/PO25927/1). The authors acknowledge financial support from 
the National Institute for Health Research (NIHR) Specialist Biomedical Research 
Centre for Mental Health at South London and Maudsley NHS Foundation Trust 
and King’s College London, and the ESRC Centre for Society and Mental Health at 
King’s College London (ESRC Reference: ES/S012567/1). This programme builds on 
research funded by the Wellcome Trust (WT094525).
Competing interests RMM has received payment for lectures from Janssen, 
Sunovian, Otsuka, Lundbeck, Angelini and Rekordati.
patient consent for publication Not required.
provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
orCId ids
Tessa Roberts http:// orcid. org/ 0000- 0001- 8584- 4162
Helen Anne Weiss http:// orcid. org/ 0000- 0003- 3547- 7936
rEFErEnCEs
 1 Saha S, Chant D, McGrath J. A systematic review of mortality in 
schizophrenia: is the differential mortality gap worsening over time? 
Arch Gen Psychiatry 2007;64:1123–31.
 2 McGrath J, Saha S, Chant D, et al. Schizophrenia: a Concise 
overview of incidence, prevalence, and mortality. Epidemiol Rev 
2008;30:67–76.
 3 Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology 
and burden of schizophrenia: findings from the global burden of 
disease study 2016. Schizophr Bull 2018;44:1195–203.
 4 McGrath J, Saha S, Welham J, et al. A systematic review of the 
incidence of schizophrenia: the distribution of rates and the influence 
of sex, urbanicity, migrant status and methodology. BMC Med 
2004;2:13.
 5 Morgan C, John S, Esan O, et al. The incidence of psychoses in 
diverse settings, INTREPID (2): a feasibility study in India, Nigeria, 
and Trinidad. Psychol Med 2016;46:1923–33.
 6 Morgan C, Hibben M, Esan O, et al. Searching for psychosis: 
INTREPID (1): systems for detecting untreated and first- episode 
cases of psychosis in diverse settings. Soc Psychiatry Psychiatr 
Epidemiol 2015;50:879–93.
 7 Cohen A, Padmavati R, Hibben M, et al. Concepts of madness in 
diverse settings: a qualitative study from the INTREPID project. BMC 
Psychiatry 2016;16:388.
9Roberts T, et al. BMJ Open 2020;10:e039004. doi:10.1136/bmjopen-2020-039004
Open access
 8 Jongsma HE, Turner C, Kirkbride JB, et al. International incidence 
of psychotic disorders, 2002-17: a systematic review and meta- 
analysis. Lancet Public Health 2019;4:e229–44.
 9 McGrath JJ. The surprisingly rich Contours of schizophrenia 
epidemiology. Arch Gen Psychiatry 2007;64:14–16.
 10 March D, Hatch SL, Morgan C, et al. Psychosis and place. Epidemiol 
Rev 2008;30:84–100.
 11 Morgan C, Charalambides M, Hutchinson G, et al. Migration, 
ethnicity, and psychosis: toward a sociodevelopmental model. 
Schizophr Bull 2010;36:655–64.
 12 Hopper K, Harrison G, Janca A. Recovery from schizophrenia: 
an international perspective: a report from the who Collaborative 
project. In: The International study of schizophrenia. Oxford 
University Press, 2007.
 13 Menezes PR, Scazufca M, Busatto GF, et al. Incidence of 
first- contact psychosis in São Paulo, Brazil. Br J Psychiatry 
2007;191:s102–6.
 14 Jongsma HE, Gayer- Anderson C, Lasalvia A, et al. Treated incidence 
of psychotic disorders in the multinational EU- GEI study. JAMA 
Psychiatry 2018;75:36–46.
 15 DeVylder JE, Kelleher I, Lalane M, et al. Association of Urbanicity 
with psychosis in low- and middle- income countries. JAMA 
Psychiatry 2018;75:678–86.
 16 Susser E, Wanderling J. Epidemiology of nonaffective acute remitting 
psychosis vs schizophrenia. sex and sociocultural setting. Arch Gen 
Psychiatry 1994;51:294–301.
 17 Van Os J, Marcelis M, Sham P, et al. Psychopathological 
syndromes and familial morbid risk of psychosis. Br J Psychiatry 
1997;170:241–6.
 18 Peralta V, Cuesta MJ. The relationship between syndromes of the 
psychotic illness and familial liability to schizophrenia and major 
mood disorders. Schizophr Res 2007;91:200–9.
 19 Tarbox SI, Addington J, Cadenhead KS, et al. Premorbid functional 
development and conversion to psychosis in clinical high- risk 
youths. Dev Psychopathol 2013;25:1171–86.
 20 Lyngberg K, Buchy L, Liu L, et al. Patterns of premorbid functioning 
in individuals at clinical high risk of psychosis. Schizophr Res 
2015;169:209–13.
 21 Morgan C, Gayer- Anderson C. Childhood adversities and 
psychosis: evidence, challenges, implications. World Psychiatry 
2016;15:93–102.
 22 Read J, van Os J, Morrison AP, et al. Childhood trauma, psychosis 
and schizophrenia: a literature review with theoretical and clinical 
implications. Acta Psychiatr Scand 2005;112:330–50.
 23 Selten J- P, van der Ven E, Termorshuizen F. Migration and psychosis: 
a meta- analysis of incidence studies. Psychol Med 2020;50:303–13.
 24 Di Forti M, Marconi A, Carra E, et al. Proportion of patients in 
South London with first- episode psychosis attributable to use of 
high potency cannabis: a case- control study. Lancet Psychiatry 
2015;2:233–8.
 25 Marconi A, Di Forti M, Lewis CM, et al. Meta- Analysis of the 
association between the level of cannabis use and risk of psychosis. 
Schizophr Bull 2016;42:1262–9.
 26 van Nierop M, Viechtbauer W, Gunther N, et al. Childhood trauma 
is associated with a specific admixture of affective, anxiety, 
and psychosis symptoms cutting across traditional diagnostic 
boundaries. Psychol Med 2015;45:1277–88.
 27 Van Os J, Jones P, Sham P, et al. Risk factors for onset and 
persistence of psychosis. Soc Psychiatry Psychiatr Epidemiol 
1998;33:596–605.
 28 Allardyce J, McCreadie RG, Morrison G, et al. Do symptom 
dimensions or categorical diagnoses best discriminate between 
known risk factors for psychosis? Soc Psychiatry Psychiatr Epidemiol 
2007;42:429–37.
 29 Demjaha A, Morgan K, Morgan C. Symptom dimensions and ethnicity 
in the AESOP first onset psychosis study. schizophrenia research. 
Amsterdam, The Netherlands: Elsevier science, 2006.
 30 Berg AO, Andreassen OA, Aminoff SR, et al. The impact of 
immigration and visible minority status on psychosis symptom 
profile. Soc Psychiatry Psychiatr Epidemiol 2014;49:1747–57.
 31 van der Ven E, Bourque F, Joober R, et al. Comparing the clinical 
presentation of first- episode psychosis across different migrant 
and ethnic minority groups in Montreal, Quebec. Can J Psychiatry 
2012;57:300–8.
 32 Oher FJ, Demjaha A, Jackson D, et al. The effect of the environment 
on symptom dimensions in the first episode of psychosis: a 
multilevel study. Psychol Med 2014;44:2419–30.
 33 Demjaha A, MacCabe JH, Murray RM. How genes and 
environmental factors determine the different neurodevelopmental 
trajectories of schizophrenia and bipolar disorder. Schizophr Bull 
2012;38:209–14.
 34 Demjaha A, Morgan K, Morgan C, et al. Combining dimensional and 
categorical representation of psychosis: the way forward for DSM- V 
and ICD-11? Psychol Med 2009;39:1943–55.
 35 Bentall RP, de Sousa P, Varese F, et al. From adversity to psychosis: 
pathways and mechanisms from specific adversities to specific 
symptoms. Soc Psychiatry Psychiatr Epidemiol 2014;49:1011–22.
 36 Quattrone D, Di Forti M, Gayer- Anderson C, et al. Transdiagnostic 
dimensions of psychopathology at first episode psychosis: findings 
from the multinational EU- GEI study. Psychol Med 2019;49:1378–91.
 37 Morgan C, Lappin J, Heslin M, et al. Reappraising the long- term 
course and outcome of psychotic disorders: the AESOP-10 study. 
Psychol Med 2014;44:2713–26.
 38 Jobe TH, Harrow M. Long- Term outcome of patients with 
schizophrenia: a review. Can J Psychiatry 2005;50:892–900.
 39 Harrow M, Grossman LS, Jobe TH, et al. Do patients with 
schizophrenia ever show periods of recovery? A 15- year multi- 
follow- up study. Schizophr Bull 2005;31:723–34.
 40 Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: 
a 15- and 25- year international follow- up study. Br J Psychiatry 
2001;178:506–17.
 41 Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review 
and meta- analysis of recovery in schizophrenia. Schizophr Bull 
2013;39:1296–306.
 42 Stain HJ, Galletly CA, Clark S, et al. Understanding the social 
costs of psychosis: the experience of adults affected by psychosis 
identified within the second Australian national survey of psychosis. 
Aust N Z J Psychiatry 2012;46:879–89.
 43 Killaspy H, White S, Lalvani N, et al. The impact of psychosis 
on social inclusion and associated factors. Int J Soc Psychiatry 
2014;60:148–54.
 44 Gayer- Anderson C, Morgan C, networks S. Social networks, support 
and early psychosis: a systematic review. Epidemiol Psychiatr Sci 
2013;22:131–46.
 45 Waghorn G, Saha S, Harvey C, et al. 'Earning and learning' in those 
with psychotic disorders: the second Australian national survey of 
psychosis. Aust N Z J Psychiatry 2012;46:774–85.
 46 Kooyman I, Dean K, Harvey S, et al. Outcomes of public concern in 
schizophrenia. Br J Psychiatry 2007;191:s29–36.
 47 Marwaha S, Johnson S, Bebbington P, et al. Rates and correlates 
of employment in people with schizophrenia in the UK, France and 
Germany. Br J Psychiatry 2007;191:30–7.
 48 Menezes NM, Arenovich T, Zipursky RB. A systematic review of 
longitudinal outcome studies of first- episode psychosis. Psychol 
Med 2006;36:1349–62.
 49 Alvarez- Jimenez M, Priede A, Hetrick SE, et al. Risk factors for 
relapse following treatment for first episode psychosis: a systematic 
review and meta- analysis of longitudinal studies. Schizophr Res 
2012;139:116–28.
 50 Díaz- Caneja CM, Pina- Camacho L, Rodríguez- Quiroga A, et al. 
Predictors of outcome in early- onset psychosis: a systematic review. 
NPJ Schizophr 2015;1:14005.
 51 Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: 
manifestations, incidence and course in different cultures. A world 
Health organization ten- country study. Psychol Med Monogr Suppl 
1992;20:1–97.
 52 Cohen A, Patel V, Thara R, et al. Questioning an axiom: better 
prognosis for schizophrenia in the developing world? Schizophr Bull 
2008;34:229–44.
 53 Demyttenaere K, Bruffaerts R, Posada- Villa J, et al. Prevalence, 
severity, and unmet need for treatment of mental disorders in the 
world Health organization world mental health surveys. JAMA 
2004;291:2581–90.
 54 Asher L, Fekadu A, Hanlon C. Global mental health and 
schizophrenia. Curr Opin Psychiatry 2018;31:193–9.
 55 Burns JK, Tomita A. Traditional and religious healers in the pathway 
to care for people with mental disorders in Africa: a systematic 
review and meta- analysis. Soc Psychiatry Psychiatr Epidemiol 
2015;50:867–77.
 56 Thirthalli J, Zhou L, Kumar K, et al. Traditional, complementary, 
and alternative medicine approaches to mental health care and 
psychological wellbeing in India and China. Lancet Psychiatry 
2016;3:660–72.
 57 Gureje O, Nortje G, Makanjuola V, et al. The role of global traditional 
and complementary systems of medicine in the treatment of mental 
health disorders. Lancet Psychiatry 2015;2:168–77.
 58 Nortje G, Oladeji B, Gureje O, et al. Effectiveness of traditional 
healers in treating mental disorders: a systematic review. Lancet 
Psychiatry 2016;3:154–70.
 59 Drew N, Funk M, Tang S, et al. Human rights violations of people 
with mental and psychosocial disabilities: an unresolved global crisis. 
Lancet 2011;378:1664–75.
10 Roberts T, et al. BMJ Open 2020;10:e039004. doi:10.1136/bmjopen-2020-039004
Open access 
 60 Thrush A, Hyder AA, Hyder A. The neglected burden of caregiving in 
low- and middle- income countries. Disabil Health J 2014;7:262–72.
 61 Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: 
a review. Pharmacoeconomics 2008;26:149–62.
 62 Caqueo- Urízar A, Gutiérrez- Maldonado J, Miranda- Castillo C. Quality 
of life in caregivers of patients with schizophrenia: a literature review. 
Health Qual Life Outcomes 2009;7:84.
 63 Chan SW- chi, SW- c C. Global perspective of burden of family 
caregivers for persons with schizophrenia. Arch Psychiatr Nurs 
2011;25:339–49.
 64 Loganathan S, Murthy SR. Experiences of stigma and discrimination 
endured by people suffering from schizophrenia. Indian J Psychiatry 
2008;50:39.
 65 Gureje O, Lasebikan VO, Ephraim- Oluwanuga O, et al. Community 
study of knowledge of and attitude to mental illness in Nigeria. Br J 
Psychiatry 2005;186:436–41.
 66 Hutchinson G, Neehall JE, Simeon DT, et al. Perceptions about 
mental illness among pre- clinical medical students in Trinidad & 
Tobago. West Indian Med J 1999;48:81–4.
 67 Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia 
and other psychoses: a 10- year follow- up of the ӔSOP first- episode 
cohort. Schizophr Bull 2015;41:664–73.
 68 Doherty AM, Gaughran F. The interface of physical and mental 
health. Soc Psychiatry Psychiatr Epidemiol 2014;49:673–82.
 69 Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. 
Acta Psychiatr Scand 2009;119:4–14.
 70 DE Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in 
people with schizophrenia: a review. World Psychiatry 2009;8:15–22.
 71 Mitchell AJ, Vancampfort D, De Herdt A, et al. Is the prevalence 
of metabolic syndrome and metabolic abnormalities increased in 
early schizophrenia? A comparative meta- analysis of first episode, 
untreated and treated patients. Schizophr Bull 2013;39:295–305.
 72 Firth J, Siddiqi N, Koyanagi A, et al. The Lancet psychiatry 
Commission: a blueprint for protecting physical health in people with 
mental illness. Lancet Psychiatry 2019;6:675–712.
 73 Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost 
and life expectancy in schizophrenia: a systematic review and meta- 
analysis. Lancet Psychiatry 2017;4:295–301.
 74 Fekadu A, Medhin G, Kebede D, et al. Excess mortality in severe 
mental illness: 10- year population- based cohort study in rural 
Ethiopia. Br J Psychiatry 2015;206:289–96.
 75 Lêng CH, Chou MH, Lin S- H, et al. Estimation of life expectancy, 
loss- of- life expectancy, and lifetime healthcare expenditures for 
schizophrenia in Taiwan. Schizophr Res 2016;171:97–102.
 76 Padmavati R. Metabolic syndrome, serious mental illnesses & 
lifestyle. Indian J Med Res 2016;143:395.
 77 Mohan V, Sandeep S, Deepa R, et al. Epidemiology of type 2 
diabetes: Indian scenario. Indian J Med Res 2007;125:217–30.
 78 Azevedo M, Alla S. Diabetes in sub- Saharan Africa: Kenya, Mali, 
Mozambique, Nigeria, South Africa and Zambia. Int J Diabetes Dev 
Ctries 2008;28:101.
 79 Joseph L. An assessment of knowledge, attitude, beliefs and risk 
perception of type 2 diabetes mellitus among the adult population of 
Trinidad and Tobago, 2016.
 80 Bebbington P, Nayani T. The psychosis screening questionnaire. Int J 
Meth Psych Res 1995:11–19.
 81 Gale NK, Heath G, Cameron E, et al. Using the framework method 
for the analysis of qualitative data in multi- disciplinary health 
research. BMC Med Res Methodol 2013;13:117.
 82 Sartorius N, Janca A, Gulbinat W. Psychiatric assessment 
instruments developed by the world Health organization. Soc 
Psychiatry Psychiatr Epidemiol 1996;31:55–69.
 83 McGuffin P, Farmer A, Harvey I. A Polydiagnostic application 
of operational criteria in studies of psychotic illness. Arch Gen 
Psychiatry 1991;48:764–70.
 84 Karterud S, Pedersen G, Loevdahl H. Global assessment of 
Functioning- Split version (S- GAF): background and scoring manual. 
Oslo, Norway: Ullevaal University Hospital, Department of Psychiatry, 
1998.
 85 World Health Organization. Who psychiatric disability assessment 
schedule. who, 1988
 86 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome 
scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
 87 Keefe RSE, Goldberg TE, Harvey PD, et al. The brief assessment of 
cognition in schizophrenia: reliability, sensitivity, and comparison with 
a standard neurocognitive battery. Schizophr Res 2004;68:283–97.
 88 Maxwell ME. Manual for the figs. Bethesda (MD: Clinical 
Neurogenetics Branch, National Institute of Mental Health, 1992.
 89 Cannon- Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid 
adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470–84.
 90 Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking 
and substance involvement screening test (assist). Addiction 
2008;103:1039–47.
 91 Scher CD, Stein MB, Asmundson GJ, et al. The childhood trauma 
questionnaire in a community sample: psychometric properties and 
normative data. J Trauma Stress 2001;14:843–57.
 92 Mollica RF. Measuring trauma, measuring torture: instructions and 
guidance on the utilization of the Harvard Program in Refugee 
Trauma's Versions of the Hopkins Symptom Checklist-25 (HSCL-25) 
& The Harvard Trauma Questionnaire (HTQ): Harvard Program in 
Refugee Trauma, 2004
 93 Motrico E, Moreno- Küstner B, de Dios Luna J, et al. Psychometric 
properties of the List of Threatening Experiences--LTE and its 
association with psychosocial factors and mental disorders 
according to different scoring methods. J Affect Disord 
2013;150:931–40.
 94 Grandón P, Jenaro C, Lemos S. Primary caregivers of schizophrenia 
outpatients: burden and predictor variables. Psychiatry Res 
2008;158:335–43.
 95 Tessler R, Gamache G. The family burden interview schedule–short 
form (FBIS/SF). Armherst: Machmer Hall, 1994.
 96 Groleau D, Young A, Kirmayer LJ. The McGill illness narrative 
interview (mini): an interview schedule to elicit meanings and modes 
of Reasoning related to illness experience. Transcult Psychiatry 
2006;43:671–91.
 97 Bonita R, Winkelmann R, Douglas KA, et al. The WHO stepwise 
approach to surveillance (STEPS) of non- communicable disease 
risk factors. Global behavioral risk factor surveillance. Boston, MA: 
Springer, 2003: 9–22.
 98 Waddell L, Taylor M. A new self- rating scale for detecting atypical or 
second- generation antipsychotic side effects. J Psychopharmacol 
2008;22:238–43.
